Wilmington Savings Fund Society FSB Makes New $787,000 Investment in GSK plc (NYSE:GSK)

Wilmington Savings Fund Society FSB acquired a new position in shares of GSK plc (NYSE:GSK - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 19,248 shares of the pharmaceutical company's stock, valued at approximately $787,000.

Other institutional investors also recently added to or reduced their stakes in the company. FMR LLC grew its stake in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company's stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Primecap Management Co. CA increased its holdings in shares of GSK by 13.9% during the 2nd quarter. Primecap Management Co. CA now owns 14,511,390 shares of the pharmaceutical company's stock worth $558,689,000 after purchasing an additional 1,773,020 shares during the period. Healthcare of Ontario Pension Plan Trust Fund bought a new stake in GSK in the second quarter valued at $52,487,000. Fisher Asset Management LLC increased its holdings in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company's stock valued at $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Finally, Hotchkis & Wiley Capital Management LLC grew its stake in shares of GSK by 30.8% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company's stock valued at $144,803,000 after purchasing an additional 833,080 shares during the last quarter. Hedge funds and other institutional investors own 15.74% of the company's stock.

GSK Stock Performance

NYSE GSK traded down $0.37 during trading on Monday, hitting $33.59. 4,915,391 shares of the company's stock traded hands, compared to its average volume of 4,162,148. The stock has a market capitalization of $69.61 billion, a price-to-earnings ratio of 22.05, a PEG ratio of 1.54 and a beta of 0.64. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The business has a 50 day moving average of $36.18 and a 200-day moving average of $39.21. GSK plc has a 12-month low of $32.83 and a 12-month high of $45.92.

GSK Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a $0.3928 dividend. This is an increase from GSK's previous quarterly dividend of $0.38. The ex-dividend date is Friday, November 15th. This represents a $1.57 dividend on an annualized basis and a yield of 4.68%. GSK's payout ratio is presently 99.35%.

Analysts Set New Price Targets

Several research firms have recently issued reports on GSK. Deutsche Bank Aktiengesellschaft lowered GSK from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. Barclays upgraded shares of GSK to a "hold" rating in a report on Tuesday, August 27th. StockNews.com upgraded GSK from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Jefferies Financial Group downgraded GSK from a "buy" rating to a "hold" rating and reduced their price target for the company from $53.00 to $39.50 in a research note on Tuesday, November 12th. Finally, Guggenheim cut GSK from a "buy" rating to a "neutral" rating in a research note on Thursday, October 31st. Seven investment analysts have rated the stock with a hold rating and four have given a strong buy rating to the company's stock. According to data from MarketBeat, GSK presently has a consensus rating of "Moderate Buy" and a consensus price target of $43.25.

Insider Activity

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm's stock in a transaction dated Friday, September 27th. The stock was purchased at an average price of $8.00 per share, for a total transaction of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares of the company's stock, valued at $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 10.00% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.